Eterna Therapeutics News

Eterna Therapeutics Launches Research To Evaluate ERNA-101's Ability To Induce And Modulate Antitumor Immunity In Ovarian And Breast Cancer Models

BenzingaDec 3 08:38 ET

Express News | Eterna: To Investigate Ability of Erna-101 to Induce, Modulate Antitumor Immunity in Ovarian Cancer, Breast Cancer Models Through Research

ReutersDec 3 08:32 ET

Eterna Therapeutics Launches Research to Evaluate Its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

GlobeNewswireDec 3 08:30 ET

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

GlobeNewswireNov 25 08:30 ET

Express News | Eterna Therapeutics Announces up to $1 Million Stock Repurchase Program

ReutersNov 25 08:30 ET

12 Health Care Stocks Moving In Monday's Pre-Market Session

BenzingaNov 18 16:05 ET

Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

BenzingaNov 18 10:15 ET

Eterna Therapeutics Regains Nasdaq Compliance and Plans Advancements in Cell Therapy for Cancer Treatment

Quiver QuantitativeNov 14 08:48 ET

Eterna Therapeutics Regains Compliance With NASDAQ for Continued Listing

GlobeNewswireNov 14 08:30 ET

Express News | Eterna Therapeutics Regains Compliance With Nasdaq for Continued Listing

ReutersNov 14 08:30 ET

Eterna Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 12 17:19 ET · Announcements

Express News | Eterna Therapeutics Inc - Targets Ind Submissions by 2026

ReutersOct 30 08:30 ET

Express News | Eterna Therapeutics Inc - Advances Lead Therapeutic Candidate Erna-101

ReutersOct 30 08:30 ET

Press Release: Eterna Therapeutics Completes Strategic Financial Restructuring With the Aim to Accelerate Its Developmental Activities and Long-Term Success

Dow JonesOct 30 08:30 ET

Express News | Eterna Therapeutics Completes Strategic Financial Restructuring With the Aim to Accelerate Its Developmental Activities and Long-Term Success

ReutersOct 30 08:30 ET

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

GlobeNewswireOct 17 08:00 ET

Eterna Therapeutics Strikes Key Deal for Disease-Fighting Tech

TipRanksSep 27 16:49 ET

Express News | Eterna Therapeutics Inc: On Sept 24 Co Entered Into License & Collaboration Agreement Effective Sept 9, 2024, With Factor Bioscience Limited

ReutersSep 27 16:21 ET

Eterna Therapeutics | 10-Q: Q2 2024 Earnings Report

SECAug 13 16:36 ET · Announcements

12 Health Care Stocks Moving In Monday's Intraday Session

BenzingaJun 3 12:31 ET